[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611609":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":44,"collaborators":47,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":74,"overallStatus":84,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Necmettin Erbakan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MIST_Cohort",null,"Men aged ≥40 years undergoing minimally invasive prostate interventions (Rezum, Urolift, Aquablation, PAE, iTind, TPLA, TUNA, TUMT) as part of routine clinical care. All participants are observed prospectively in a single registry cohort without assignment to treatment.",[13],"Other: No intervention",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"No intervention","Participants receive standard-of-care minimally invasive prostate interventions determined by their treating clinicians. The study does not assign or alter any treatment; it only observes outcomes.",[9],[20],{"name":21,"affiliation":5,"role":22},"Selçuk Güven, MD, PhD","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Selim Soytürk, MD","CONTACT","+905077299193","selim.soyturk@erbakan.edu.tr",[30],{"facility":31,"status":10,"city":32,"state":10,"zip":33,"country":34,"countryCode":10,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Necmettin Erbakan University Medical Faculty Hospital","Konya","42250","Turkey (Türkiye)",{"type":36,"coordinates":37},"Point",[38,39],32.48464,37.87135,{"lat":39,"lon":38},[42],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":43},"selimsoyturk06@gmail.com",{"type":22,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Selim Soyturk","Urologist \u002F Coordinating Investigator",[48,50,52],{"name":49,"class":6},"University Hospital Southampton NHS Foundation Trust",{"name":51,"class":6},"Medical University of Graz",{"name":53,"class":6},"Hannover Medical School","100611609","minimally-invasive-prostate-interventions-registry-mist-study-100611609",false,"NCT07242807","Minimally Invasive Prostate Interventions Registry (MIST Study)","Evaluation of Clinical and Functional Outcomes After Minimally Invasive Prostate Interventions: A Multicenter Prospective REDCap Registry (MIST Study)","MIST","Inclusion Criteria:\n\n* Male patients aged ≥40 years\n* Diagnosis of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) or benign prostatic obstruction (BPO)\n* Undergoing a minimally invasive prostate intervention (Rezum, UroLift, Aquablation, PAE, iTind, TPLA, TUNA, TUMT) as part of standard clinical care\n* Ability and willingness to attend scheduled follow-up visits\n* Prospective participants able to provide written informed consent\n* Retrospective cases eligible if data are fully de-identified and inclusion is approved by local ethics\u002FIRB authorities\n\nExclusion Criteria:\n\n* Active urinary tract infection at the time of treatment\n* ASA physical status ≥5\n* Prior pelvic radiotherapy resulting in severe bladder dysfunction\n* Severe cognitive impairment or inability to participate in follow-up\n* Missing essential baseline data (for retrospective entries)\n* Patients receiving experimental or investigational prostate devices or therapies outside routine clinical care","MALE","40 Years",{"count":65,"type":66},2000,"ESTIMATED","72 Months","OBSERVATIONAL","This study is a multicenter prospective patient registry designed to evaluate clinical, functional, and safety outcomes after minimally invasive prostate interventions (MIST) performed for benign prostatic obstruction (BPO) secondary to benign prostatic hyperplasia (BPH). The interventions included in this registry represent standard-of-care treatment options and may include Rezum water vapor therapy, UroLift prostatic urethral lift, Aquablation, prostatic artery embolization (PAE), iTind, transperineal laser ablation (TPLA), transurethral needle ablation (TUNA), and transurethral microwave therapy (TUMT).\n\nThe registry collects standardized data using a secure REDCap platform from participating international centers. Data elements include demographic characteristics, comorbidities, medication use, laboratory parameters, prostate volume assessments, uroflowmetry, post-void residual measurements, patient-reported symptom scores, sexual function assessments, intraoperative details, complications (classified using Clavien-Dindo), and postoperative recovery parameters. Follow-up visits occur at 1, 3, 6, 12, 24, and 36 months, with an optional extended follow-up at 72 months to assess long-term durability and reintervention-free survival.\n\nThe primary aim of the study is to evaluate improvements in urinary symptoms (IPSS), quality of life, maximum urinary flow rate (Qmax), and post-void residual volume (PVR) following MIST procedures. Secondary objectives include assessing perioperative safety, catheterization duration, predictors of treatment success or failure, need for reintervention, and long-term preservation of continence and sexual function.\n\nThis registry is observational and does not assign or modify any treatment. All procedures are performed based on local clinical practice and physician judgment. Prospective participants provide informed consent. Data collected will be used to generate real-world evidence to guide patient selection, optimize procedural outcomes, and compare clinical performance across different minimally invasive prostate interventions.",[71,72,73],"Benign Prostatic Hyperplasia (BPH)","Minimal Invasive Surgery","LUTS",[60,75,76,77,78,79,80,81,82,83],"Minimally Invasive Surgical Therapy","Rezum","UroLift","Aquablation","Prostatic Artery Embolization","iTind","TPLA","Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms","NOT_YET_RECRUITING","2026-03-28",{"date":87,"type":88},"2026-03-31","ACTUAL",{"date":90,"type":66},"2026-03-25",{"date":92,"type":66},"2031-12-30",{"name":5,"class":6},1]